People: Thermo Fisher Scientific Inc (TMO)
TMO on New York Consolidated
85.69USD
23 May 2013
85.69USD
23 May 2013
Price Change (% chg)
$-0.59 (-0.68%)
$-0.59 (-0.68%)
Prev Close
$86.28
$86.28
Open
$85.72
$85.72
Day's High
$86.03
$86.03
Day's Low
$84.98
$84.98
Volume
2,213,640
2,213,640
Avg. Vol
2,544,165
2,544,165
52-wk High
$88.08
$88.08
52-wk Low
$48.14
$48.14
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Jim Manzi |
2007 | Independent Chairman of the Board | |
Marc Casper |
45 | 2009 | President, Chief Executive Officer, Director |
Peter Wilver |
53 | 2006 | Chief Financial Officer, Senior Vice President |
Alan Malus |
53 | 2012 | Executive Vice President, President - Analytical Technologies |
Seth Hoogasian |
58 | 2006 | Senior Vice President, General Counsel, Secretary |
Thomas Loewald |
49 | 2012 | Senior Vice President, President - Laboratory Products |
Edward Pesicka |
45 | 2008 | Senior Vice President, President - Customer Channels |
Andrew Thomson |
48 | 2012 | Senior Vice President, President - Specialty Diagnostics |
Peter Hornstra |
53 | 2007 | Vice President, Chief Accounting Officer |
Nelson Chai |
47 | 2010 | Independent Director |
C. Martin Harris |
56 | 2012 | Independent Director |
Tyler Jacks |
52 | 2009 | Independent Director |
Judy Lewent |
64 | 2008 | Independent Director |
Thomas Lynch |
58 | 2009 | Independent Director |
William Parrett |
67 | 2008 | Independent Director |
Lars Sorensen |
56 | 2011 | Independent Director |
Scott Sperling |
56 | 2006 | Independent Director |
Elaine Ullian |
65 | 2001 | Independent Director |
Kenneth Apicerno |
Vice President, Investor Relations |
Biographies
| Name | Description |
|---|---|
Jim Manzi |
Mr. Jim P. Manzi is Independent Chairman of the Board of Thermo Fisher Scientific Inc., since May 11, 2007. He was also Chairman of the Board from January 2004 to November 2006. He has been the Chairman of Stonegate Capital, a firm he formed to manage private equity investment activities in technology startup ventures, primarily related to the internet, since 1995. From 1984 until 1995, he served as the Chairman, President and Chief Executive Officer of Lotus Development Corporation, a software manufacturer that was acquired by IBM Corporation in 1995. |
Marc Casper |
Mr. Marc N. Casper is President, Chief Executive Officer, Director of Thermo Fisher Scientific Inc., since October 15, 2009. He has been a director of the Company since October 2009. He has been President and Chief Executive Officer of the Company since October 2009. He served as the Company’s Chief Operating Officer from May 2008 to October 2009 and was Executive Vice President from November 2006 to October 2009. Prior to being named Executive Vice President, he was Senior Vice President from December 2003 to November 2006. Prior to joining the Company, Mr. Casper served as president, chief executive officer and a director of Kendro Laboratory Products. Mr. Casper is also a director of Zimmer Holdings, Inc. and within the last five years was a director of The Advisory Board Company. |
Peter Wilver |
Mr. Peter M. Wilver is Chief Financial Officer, Senior Vice President of Thermo Fisher Scientific Inc. Mr. Wilver was appointed Senior Vice President in November 2006 and Chief Financial Officer in October 2004. He was Vice President from October 2004 to November 2006. |
Alan Malus |
Mr. Alan J. Malus is Executive Vice President, President - Analytical Technologies of Thermo Fisher Scientific Inc., since January 2012. He was President, Laboratory Products from July 2008 to January 2012 and was appointed Senior Vice President of Thermo Fisher Scientific in November 2006. Prior to Thermo’s merger with Fisher, Mr. Malus was group president of distribution and services for Fisher, where he focused on growing the company’s customer channel businesses serving research, healthcare, education and safety markets. Mr. Malus joined Fisher in 1998 and served in a variety of management roles. |
Seth Hoogasian |
Mr. Seth H. Hoogasian is Senior Vice President, General Counsel, Secretary of Thermo Fisher Scientific Inc. Mr. Hoogasian was appointed Senior Vice President in November 2006, Secretary in 2001 and General Counsel in 1992. He was Vice President from 1996 to November 2006. |
Thomas Loewald |
Mr. Thomas W. Loewald is Senior Vice President, President - Laboratory Products of Thermo Fisher Scientific Inc., since January 1, 2012. He was appointed President of the Laboratory Equipment business in August 2008, and was President of the Environmental Instruments business from October 2006 until August 2008. |
Edward Pesicka |
Mr. Edward A. Pesicka is Senior Vice President, President - Customer Channels of Thermo Fisher Scientific Inc., since July 2008. He was President, Research Market from November 2006 to July 2008. Prior to Thermo’s merger with Fisher, Mr. Pesicka was Vice President and General Manager of Fisher’s U.S. research market business from January 2004 to November 2006. |
Andrew Thomson |
Mr. Andrew J. Thomson is Senior Vice President, President - Specialty Diagnostics of Thermo Fisher Scientific Inc., since February 2012. He was President of the Clinical Diagnostics business from October 2009 to May 2012 and was Vice President and General Manager for North America for the Microbiology business from January 2009 until October 2009. Before joining Thermo Fisher Scientific, Mr. Thomson spent the prior fifteen years in the diagnostics industry in a variety of marketing and commercial roles of increasing responsibility with Roche Diagnostics and prior to that, Dade Behring. |
Peter Hornstra |
Mr. Peter E. Hornstra is Vice President, Chief Accounting Officer of Thermo Fisher Scientific Inc. Mr. Hornstra was appointed Vice President in February 2007 and Chief Accounting Officer in January 2001. He was Corporate Controller from January 1996 to February 2007. |
Nelson Chai |
Mr. Nelson J. Chai is Independent Director of Thermo Fisher Scientific Inc., since December 10, 2010. He is President of CIT Group Inc., a bank holding company that provides lending, advisory and leasing services to small and middle market businesses. He joined CIT Group in June 2010 as Executive Vice President, Chief Administrative Officer and head of strategy, and was appointed to his current position in August 2011. Previously, he was President, Asia-Pacific for Bank of America Corporation beginning in December 2008, and Executive Vice President and Chief Financial Officer of Merrill Lynch & Co., a financial services firm, from December 2007 to December 2008. Prior to that Mr. Chai was Executive Vice President and Chief Financial Officer of NYSE Euronext, a stock exchange group, from March 2006 to December 2007, and Chief Financial Officer of Archipelago Holdings, L.L.C., an electronic stock exchange, from June 2000 to March 2006. |
C. Martin Harris |
Dr. C. Martin Harris, M.D., is Independent Director of Thermo Fisher Scientific Inc., since March 30, 2012. Since 2009, Dr. Harris has been the Chief Strategy Officer of The Cleveland Clinic Foundation, a multi-specialty academic medical center, and since 1996, he has been the Chief Information Officer and Chairman of the Information Technology Division of and a Staff Physician for The Cleveland Clinic Hospital and The Cleveland Clinic Foundation Department of General Internal Medicine. Additionally, since 2000, he has been Executive Director of e-Cleveland Clinic, a series of e-health clinical programs offered over the internet. Dr. Harris is also a director of HealthStream Inc. and Invacare Corporation. |
Tyler Jacks |
Dr. Tyler Jacks, Ph.D. is Independent Director of Thermo Fisher Scientific Inc., since May 26, 2009. He is the David H. Koch Professor of Biology at the Massachusetts Institute of Technology (MIT) and director of the David H. Koch Institute for Integrative Cancer Research. He joined the MIT faculty in 1992 and was director of its Center for Cancer Research from 2001 to 2008. Since 2002, Dr. Jacks has been an investigator with the Howard Hughes Medical Institute. Dr. Jacks is also a director of Amgen Inc. |
Judy Lewent |
Ms. Judy C. Lewent is Independent Director of Thermo Fisher Scientific Inc., since May 27, 2008. She was Chief Financial Officer of Merck & Co., Inc., a global pharmaceutical company, from 1990 until her retirement in 2007. She was also Executive Vice President of Merck from February 2001 through her retirement and had additional responsibilities as President, Human Health Asia from January 2003 until July 2005, when she assumed strategic planning responsibilities for Merck. Ms. Lewent is also a director of Motorola Solutions, Inc. and GlaxoSmithKline plc, and within the last five years was a director of Dell, Inc. and Motorola, Inc. |
Thomas Lynch |
Mr. Thomas J. Lynch is Independent Director of Thermo Fisher Scientific Inc., since May 26, 2009. He is Chairman and Chief Executive Officer of TE Connectivity Ltd. (formerly Tyco Electronics Ltd.), a global provider of engineered electronic components, network solutions, undersea telecommunication systems and specialty products. He joined Tyco International in 2004 as President of Tyco Engineered Products and Services and was appointed Chief Executive Officer in January 2006, when Tyco Electronics was formed and later became an independent, separately traded entity. Mr. Lynch is also a director of TE Connectivity Ltd., and in January 2013 was elected Chairman of the Board. |
William Parrett |
Mr. William G. Parrett is Independent Director of Thermo Fisher Scientific Inc., since June 27, 2008. Until his retirement in November 2007, he served as Chief Executive Officer of Deloitte Touche Tohmatsu, a global accounting firm. Mr. Parrett joined Deloitte in 1967, and served in a series of roles of increasing responsibility. Mr. Parrett serves as a director of the Blackstone Group LP, Eastman Kodak Company and UBS AG, and is chairman of their Audit Committees. |
Lars Sorensen |
Mr. Lars Rebien Sorensen is Independent Director of Thermo Fisher Scientific Inc., since July 12, 2011. He has been President and Chief Executive Officer of Novo Nordisk A/S, a global healthcare company with a position in diabetes care, since November 2000. He has held various senior management roles at Novo Nordisk since joining the company in 1982. Mr. Sørensen also currently serves as a member of the supervisory board of Bertelsmann AG, a worldwide media company based in Germany, and is a director of Danmarks Nationalbank, Denmark (the national bank of Denmark). Within the last five years, he was a director of ZymoGenetics Inc. and Dong Energy A/S. |
Scott Sperling |
Mr. Scott M. Sperling is Independent Director of Thermo Fisher Scientific Inc., since November 9, 2006. Prior to the merger of Thermo Electron Corporation and Fisher Scientific International Inc., he was a director of Fisher Scientific from January 1998 to November 2006. He has been employed by Thomas H. Lee Partners, L.P., a leveraged buyout firm, and its predecessor, Thomas H. Lee Company, since 1994. Mr. Sperling currently serves as Co-President of Thomas H. Lee Partners, L.P. Mr. Sperling is also a director of CC Media Holdings, Inc., and within the last five years was a director of Warner Music Group Corp. and Vertis, Inc. |
Elaine Ullian |
Ms. Elaine S. Ullian is Independent Director of Thermo Fisher Scientific Inc., since July 2001. She was the President and Chief Executive Officer of Boston Medical Center, a 550-bed academic medical center affiliated with Boston University, from July 1996 to her retirement in January 2010. Ms. Ullian is also a director of Vertex Pharmaceuticals, Inc. and Hologic Inc., and within the last five years was a director of Valeant Pharmaceuticals International. |
Kenneth Apicerno |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Jim Manzi |
-- |
Marc Casper |
13,555,100 |
Peter Wilver |
3,714,690 |
Alan Malus |
4,727,350 |
Seth Hoogasian |
2,071,310 |
Thomas Loewald |
2,500,900 |
Edward Pesicka |
4,208,900 |
Andrew Thomson |
-- |
Peter Hornstra |
-- |
Nelson Chai |
-- |
C. Martin Harris |
-- |
Tyler Jacks |
-- |
Judy Lewent |
-- |
Thomas Lynch |
-- |
William Parrett |
-- |
Lars Sorensen |
-- |
Scott Sperling |
-- |
Elaine Ullian |
-- |
Kenneth Apicerno |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Jim Manzi |
0 | 0 |
Marc Casper |
1,031,900 | 12,760,540 |
Peter Wilver |
588,906 | 5,207,030 |
Alan Malus |
164,740 | 3,114,860 |
Seth Hoogasian |
490,481 | 6,847,450 |
Thomas Loewald |
30,680 | 675,736 |
Edward Pesicka |
80,800 | 1,122,890 |
Andrew Thomson |
0 | 0 |
Peter Hornstra |
0 | 0 |
Nelson Chai |
0 | 0 |
C. Martin Harris |
0 | 0 |
Tyler Jacks |
0 | 0 |
Judy Lewent |
0 | 0 |
Thomas Lynch |
0 | 0 |
William Parrett |
0 | 0 |
Lars Sorensen |
0 | 0 |
Scott Sperling |
0 | 0 |
Elaine Ullian |
0 | 0 |
Kenneth Apicerno |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
MALUS ALAN J |
4,000 | $84.43 |
SPERLING SCOTT M |
8,000 | $84.65 |
THOMSON ANDREW J |
12,700 | $83.65 |
MANZI JIM P |
7,500 | $82.78 |
ULLIAN ELAINE S |
8,000 | $82.73 |
THOMSON ANDREW J |
12,700 | $46.56 |
MALUS ALAN J |
1,813 | $76.43 |
LOEWALD THOMAS W |
693 | $76.43 |
THOMSON ANDREW J |
210 | $76.43 |
WILVER PETER M |
1,745 | $76.43 |
HORNSTRA PETER E |
155 | $76.43 |
PESICKA EDWARD A |
1,813 | $76.43 |
HOOGASIAN SETH H |
586 | $76.43 |
LOEWALD THOMAS W |
4,761 | $74.57 |
PESICKA EDWARD A |
5,936 | $74.78 |
MALUS ALAN J |
6,694 | $74.78 |
WILVER PETER M |
5,058 | $74.78 |
HORNSTRA PETER E |
222 | $74.78 |
CASPER MARC N |
22,955 | $74.78 |
THOMSON ANDREW J |
2,411 | $74.78 |
LOEWALD THOMAS W |
2,522 | $74.78 |
HOOGASIAN SETH H |
1,592 | $74.78 |
THOMSON ANDREW J |
13,700 | $0.00 |
CASPER MARC N |
20,589 | $0.00 |
CASPER MARC N |
50,400 | $0.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
